Jeg har klaget til Ronny… kanskje de hørte på meg?
8 days to go 
1 Like
Exactly stockDZ
Add to this Asia…and potentially pancreatic cancer, see my analysis posted this weekend.
I think I might need to revisit the analysis. At the moment those upsides are only included with low probabilities.
After todays events I think in particular the Asian upside is in need of an upgraded probabililty.
2 Likes
@Investor, waiting impatiently on updates on abscopal effect of fimachem from extension study as studying the immune response is one of the objectives. I think half of the answer is already there
2 Likes
StockDZ
I posted some highlights and a graph during the weekend. Was too busy this week so far to compile it and finish the write up for the Seeking Alpha article. Expect to be finished later this week.
By the way, since Seeking Alpha are only accepting real articles for tickers traded in United States, it will have to be a blog article.
I was pondering whether I could find a way to publish it through an article on one of the big pharmas, like Merck or Novartis. The reason for doing this is that you would obviously reach a much broader audience and potentially spur some interest from biotech specialist investors. I was trying out a couple of ideas, like spinning on the top 10 fimaNac collaboration. However, I concluded so far that the editors would probably spot the intention and refuse the article.
But, I am open to any advice, from the Tekinvestor community on this, which could also be a collaborative effort, if someone would volunteer to help out on making the introductory write-up where we link a top 10 pharma to PCI Biotech. Could that person possibly be you, StockDZ or Snøffelen?
I was playing with some titles already:
“Will this biotech company be [top 10 pharma} next aquisition?”
“Is [top 10 pharma] PCI Biotechs secret partner?”
Edit: Looks like Astellas and Takeda can be traded OTC in US, so fimaChem partnering could be another idea.
All depends on your intentions, but personally I would avoid what might sound like a propaganda or speculation and make it rather more technology and patients centered based on facts /data/guiding we already have
Agreed. This is a long shot and a time-consuming one.
Maybe I spent my time better on trading PCIB-T 
1 Like
5 Likes
Nå sender selskapet ut et helt klart signal til eksisterende aksjonærer ved å tegne seg for aksjer på den aller første dagen tegningsrettene er i omsetning.
“Vi har trua” “Vi skal lykkes”
Det virker som at ingen så den komme 
Det virker også som at de meldingene skal spres utover i tegningsperioden også da det er flere insidere med tegningsretter.
3 Likes
Joda jeg hadde forventet at styreformannen ville tegne seg. Og han gjør det rett etter at prospektet er ute. Han kjøpte for million-beløp for lenge siden og jammen hoster han ikke opp millionbeløp enda en gang. Flott. Det bør bli en god dag i pcib-aksjen i dag i alle fall.
3 Likes
Utrolig positivt at en av de personene som kjenner best til Pcib tegner seg for over en million kroner.
Men over til diskusjonene om Asia og partner. Klart det kan være mange grunner til at Pcib har droppet partnerkonferanse i Asia. Men at de gjør det for at Asia ikke er prioritert etter at emisjonen er på plass, den kjøper jeg bare ikke. Og det er av de to grunnen jeg har nevnt, partner og siter i Asia åpner døren til et gigantisk marked i tillegg til at det kan medføre at PF2 kan bli gjennomført enda raskere.
Og i prospektet står det jo at de ser på partner ALTERNATIVER, så tolker det man slavisk så står man muligens med ulike alternativer nå som vurderes opp mot hverandre.
Hadde vært fint om ledelsen kunne opplyst mer detaljer rundt hvordan de vurderer Asia og om hvilke konkrete partneralternativer de ser for seg.
2 Likes
Blir meget overrasket (positivt sådan) om det kommer flere innsidehandler. Ledelsen har opsjoner med strike price langt lavere enn emisjonskurs. Så jeg vil anta at deres T-retter blir solgt. Det er mest logisk. Ledelsen i selskapet har 180 603 aksjer. Det vil gi 86 689 tegningsretter som utgjør 0,72 % av totalen (12 millioner aksjer). Innsidekjøp fra disse gutta hadde vært 
5 Likes
Jeg tipper det blir salg av rettighetene og kjøpt aksjer for beløpet de får fra salget.
1 Like
Nå er det vel bare å fortsette venteøvelsen igjen. Snart kommer tida, den gode fine tida…
2 Likes
En ting er sikkert, saa snart emisjonen er unnagjort, vil PCIB stige til gamle hoeyder. Dette er som aa plukke penger paa gata. Styreformann handler ikke aksjer for 1,2 millioner hvis han ikke forventer mange positive nyheter fremover.
4 Likes
ESMO Immuno-Oncology Congress 2018. Mon tro hvilken av disse fristene PCIB vil forholde seg til:
Regular abstract submission deadline 26 September 2018, 21:00 hrs CEST
Late-breaking abstract 6 November 2018, 21:00 hrs CET
6 Likes
Late-breaking abstract 6 November 2018, 21:00 hrs CET
Kommer vel en liten FimaVacc inn her eller? 
1 Like
Veldig skuffa over dagens utvikling. Håper folk snører igjen sekken ennå mere i morgen. På en annen side vil det jo også da være noen som må selge på slutten av perioden som igjen kan føre til at kursen tvinges ned, så det er ikke enkelt dette.
Det som nå er synd er jo hvis rettene trades opp og ned for tradere å tjene penger mens pcib kursen står på stedet hvil…
Frykter at det vil stå seg slik helt til enten en storfisk vil inn eller vi får noen nyheter…
1 Like
PCI Biotech: Mandatory notification regarding exercise and trade of subscription rights
Oslo, September 20, 2018 - Overview of mandatory notification regarding exercise and trade of subscription rights. Management and the board of directors of PCI Biotech Holding ASA (“PCI Biotech” or “the Company”) are all supportive to the share issue resolved by the extraordinary general meeting 14 September 2018. In total the transactions disclosed herein leads to a net increase in shareholding by primary insiders of PCI Biotech of 53,348 shares.
The following transactions are made at 20 September 2018:
Per Walday, CEO, has subscribed for 3,167 new shares in the Company at a subscription price of NOK 30 per share by exercising 3,167 subscription rights in the Company’s ongoing rights issue and has simultaneously sold his remaining 28,096 subscription rights at an average price of NOK 4.71 per subscription right. The sale of the subscription rights are made to finance all of the subscription rights exercised. After the transactions, Per Walday will have a total shareholding in the Company of 68,300 shares and 104,000 unexercised stock options in relation to the Company’s share option scheme.Ronny Skuggedal, CFO, has subscribed for 3,234 new shares in the Company at a subscription price of NOK 30 per share by exercising 3,234 subscription rights in the Company’s ongoing rights issue and has simultaneously sold his remaining 8,797 subscription rights at an average price of NOK 4.71 per subscription right. The sale of the subscription rights are made to finance parts of the subscription rights exercised. After the transaction, Ronny Skuggedal will have a total shareholding in the Company of 28,300 shares and 116,000 unexercised stock options in relation to the Company’s share option scheme.
Kristin Eivindvik, PD, has subscribed for 852 new shares in the Company at a subscription price of NOK 30 per share by exercising 852 subscription rights in the Company’s ongoing rights issue and has simultaneously sold her remaining 7,763 subscription rights at an average price of NOK 4.71 per subscription right. The sale of the subscription rights are made to finance all of the subscription rights exercised. After the transactions, Kristin Eivindvik will have a total shareholding in the Company of 18,800 shares and 33,500 unexercised stock options in relation to the Company’s share option scheme.
Anders Høgset, CSO, has subscribed for 844 new shares in the Company at a subscription price of NOK 30 per share by exercising 844 subscription rights in the Company’s ongoing rights issue and has simultaneously sold his remaining 29,134 subscription rights at an average price of NOK 4.71 per subscription right. After the transactions, Anders Høgset will have a total shareholding in the Company of 63,300 shares and 66,000 unexercised stock options in relation to the Company’s share option scheme.
Gaël L’Hévéder, CBDO, has sold all his 4,800 subscription rights at an average price of NOK 4.71 per subscription right. After the transaction, Gaël L’Hévéder have a total shareholding in the Company of 10,000 shares and 106,000 unexercised stock options in relation to the Company’s share option scheme.
In addition, the following transactions were made by the chairman and two members of PCI Biotech.s board of directors at 19 September 2018 and disclosed the same day.
The Chairman Hans Peter Bøhn subscribed for 40,106 new shares in PCI Biotech Holding ASA (the “Company”) at 19 September 2018 (the transaction was also disclosed 19 September 2018) at a subscription price of NOK 30 per share by exercising all his 40,106 subscription rights allocated in the Company’s ongoing rights issue. After the transaction, Hans Peter Bøhn will have a total shareholding in the Company of 123,662 shares.
The board member Lars Viksmoen subscribed for 1,920 new shares in PCI Biotech Holding ASA (the “Company”) at 19 September 2018 (the transaction was also disclosed 19 September 2018) at a subscription price of NOK 30 per share by exercising all his 1,920 subscription rights allocated in the Company’s ongoing rights issue through his wholly owned company, Stocken Invest AS. In addition, Stocken Invest AS bought 1,580 subscription rights at an average price of NOK 4.40 per subscription right and subsequently exercised the 1,580 acquired subscription rights. After the transactions, Stocken Invest AS will have a total shareholding in the Company of 7,500 shares. Stocken Invest AS has previously entered into a guarantee agreement of NOK 1,000,000 in relation to the rights issue, and the exercise of subscription rights will, in compliance with the guarantee agreement, reduce the guarantee liability correspondingly.
The board member Christina Herder subscribed for 1,645 new shares in PCI Biotech Holding ASA (the “Company”) at 19 September 2018 (the transaction was disclosed the same day) at a subscription price of NOK 30 per share by exercising 1,645 of her allocated subscription rights in the Company’s ongoing rights issue. In addition, she sold her remaining 2,365 subscription rights at an average price of NOK 4.40 per subscription right. After the transactions, Christina Herder will have a total shareholding in the Company of 10,000 shares.
Reference is made to the Prospectus dated 17 September 2018 for further information about the terms of the rights issue.
Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, NO-0379 Oslo.
Ronny Skuggedal, CFO, [email protected], Mobile: +47 9400 5757.This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Nyheten er levert av GlobeNewswire.
http://www.netfonds.no/quotes/release.php?id=20180920.GlobeNewswire.GNW1000099882-en
5 Likes